Endocrine Tumor Genetics

The Endocrine Tumor Genetics Program helps to identify and provide comprehensive, coordinated medical care for families that have a hereditary risk for endocrine tumors. Our program is a collaboration between the Center for Cancer Risk Assessment (CCRA) and Thyroid Associates at Massachusetts General Hospital, and includes specialists in both endocrinology and genetics. Patients with pathogenic variants in hereditary endocrine tumor genes are managed comprehensively with our team of endocrinologists and genetic counselors. We also provide risk assessment for patients interested in an evaluation for hereditary endocrine tumors. During the initial genetics consultation, family history is carefully reviewed. If your personal or family history suggests a possible genetic risk, we will discuss the option of genetic.

    Related Conference of Endocrine Tumor Genetics

    May 08-09, 2025

    5th European Endocrinology and Diabetes Congress

    Madrid, Spain
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Paris, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    October 30-31, 2025

    5th Annual Summit on Diabetes and Endocrinology

    Paris, France
    November 06-07, 2025

    8th Annual Meeting on Diabetes and Endocrinology

    Dubai, UAE
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Paris, France
    March 26-27, 2026

    7th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands

    Endocrine Tumor Genetics Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in